DBV Technologies annonce le placement d’ADS pour un montant d’environ 50 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq

DBV Technologies announced the placement of approximately $50 million in American Depositary Shares (ADS) with RA Capital Management through its At-The-Market (ATM) program on Nasdaq. The company will issue 18.288 million new ordinary shares at $13.67 per ADS, representing a 5.82% dilution to existing shareholders. The transaction is expected to close on August 3, 2026.

07/30/2026, 5:40 PM • GlobeNewswire

DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq

DBV Technologies announced the sale of approximately $50 million in American Depositary Shares (ADSs) through its At-The-Market program on Nasdaq. The company issued 18,288,220 new ordinary shares (3,657,644 ADSs) at $13.67 per ADS to RA Capital Management through Citizens JMP Securities. The issuance represents a 5.82% dilution to existing shareholders and is expected to close on August 3, 2026.

07/30/2026, 5:40 PM • GlobeNewswire

DBV Technologies dépose un prospectus relatif à son Programme At-The-Market (ATM) pour un montant pouvant atteindre 150 millions de dollars

DBV Technologies has filed a new S-3ASR registration statement with the SEC to renew its at-the-market (ATM) offering program for up to $150 million in American Depositary Shares (ADSs). The company plans to use proceeds primarily for manufacturing capacity expansion, pediatric BLA submissions for peanut allergy treatment, and product development. The program was established with Citizens JMP Securities as the placement agent.

07/17/2026, 5:00 PM • GlobeNewswire

DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing

DBV Technologies announced it has completed extensive discussions with the FDA regarding its Biologics License Application (BLA) for the VIASKIN® Peanut Patch in children aged 4-7 years. The FDA did not request additional data, but DBV will incorporate feedback on data organization and formatting before submitting the BLA in Q3 2026.

06/29/2026, 4:00 PM • GlobeNewswire

DBV Technologies fait le point sur le dépôt du dossier BLA pour le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans; la Société travaille en collaboration avec la FDA afin d'optimiser le processus d'examen en vue du dépôt du dossier

DBV Technologies announced it has completed in-depth discussions with the FDA regarding the Biologics License Application (BLA) for VIASKIN® Peanut patch for children aged 4-7 years. The FDA did not request additional data, and DBV plans to submit the BLA in Q3 2026 after incorporating FDA feedback on data organization and structuring for CMC and biostatistical elements.

06/29/2026, 4:00 PM • GlobeNewswire

DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference

DBV Technologies announced that CEO Daniel Tassé will not participate in the previously scheduled fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, due to unavoidable travel disruption. The company will still participate in 1-on-1 investor meetings at the event in Miami, FL.

06/09/2026, 7:00 AM • GlobeNewswire

DBV Technologies révise sa participation à la 47ème conférence annuelle Global Healthcare organisée par Goldman Sachs

DBV Technologies announced that its management will participate in one-on-one investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026 in Miami. However, CEO Daniel Tassé will not participate in the planned informal discussion due to unexpected travel disruptions.

06/09/2026, 7:00 AM • GlobeNewswire

DBV Technologies présente de nouvelles données positives issues de l’étude de phase 3 VITESSE, et un aperçu de l’étude THRIVE récemment initiée à l’occasion du Congrès de l’EAACI 2026

DBV Technologies announced positive results from its Phase 3 VITESSE study showing that the VIASKIN® Peanut patch demonstrated statistically significant efficacy versus placebo in peanut-allergic children aged 4-7 years with concurrent atopic conditions including asthma, food allergies, and atopic dermatitis. The company also presented the design of its Phase 2 THRIVE study evaluating the patch in infants aged 6-12 months with peanut allergy, aiming to enable unrestricted peanut consumption after three years of treatment.

06/08/2026, 4:35 PM • GlobeNewswire

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

DBV Technologies announced positive Phase 3 VITESSE study results showing the VIASKIN® Peanut Patch demonstrated statistically significant efficacy versus placebo in children aged 4-7 years with peanut allergy who also have atopic comorbidities such as asthma, food allergies, or atopic dermatitis. The company also previewed its newly initiated Phase 2 THRIVE study, which will evaluate the patch's efficacy in infants aged 6-12 months with peanut allergy over three years of treatment.

06/08/2026, 4:35 PM • GlobeNewswire

DBV Technologies annonce le screening du premier participant de l’étude clinique de phase 2 THRIVE pour le patch VIASKIN® Peanut chez les nourrissons âgés de 6 à 12 mois allergiques à l’arachide

DBV Technologies announced the first participant screening in the THRIVE phase 2 clinical trial evaluating the efficacy and safety of VIASKIN® Peanut patch in infants aged 6-12 months with peanut allergies. The study aims to enable ad libitum peanut consumption through early intervention immunotherapy, building on positive results from earlier trials in older children.

06/02/2026, 7:40 PM • GlobeNewswire

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

DBV Technologies announced the first participant has been screened in the THRIVE Phase 2 clinical study evaluating the efficacy and safety of the VIASKIN® Peanut Patch in infants ages 6-12 months with peanut allergy. The study will assess whether the patch can enable ad lib (unrestricted) peanut consumption through epicutaneous immunotherapy (EPIT), building on positive results from earlier trials in older age groups.

06/02/2026, 7:40 PM • GlobeNewswire

Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight

The US eosinophilic esophagitis market is projected to grow at 13.2% CAGR through 2036, driven by increased disease awareness, standardized diagnostics, and high relapse rates. The market was valued at $647 million in 2025, with emerging therapies from major pharmaceutical companies expected to transform the treatment landscape, including TSLP inhibitors, glucocorticoid receptor agonists, and immunomodulators.

04/13/2026, 1:00 PM • GlobeNewswire

Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2026

DBV Technologies announced the filing of its 2025 Annual Report on Form 10-K and Universal Registration Document on March 26, 2026. The company reported full year 2025 financial results and provided a business update on its VIASKIN® Peanut Patch clinical development programs. As of March 31, 2026, the company had 296,042,447 total shares composing its capital with 295,914,379 net voting rights.

04/02/2026, 4:30 PM • GlobeNewswire

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

DBV Technologies announced the filing of its 2025 Annual Report on Form 10-K and Universal Registration Document as of March 31, 2026. The company reported full year 2025 financial results and provided a business update on its VIASKIN® Peanut Patch clinical development programs. As of the reporting date, the company had 296,042,447 total shares outstanding with 295,914,379 net voting rights.

04/02/2026, 4:30 PM • GlobeNewswire

DBV Technologies présente des données positives supplémentaires de l’étude de phase 3 VITESSE à l’occasion du congres annuel AAAAI

DBV Technologies announced positive additional data from the Phase 3 VITESSE study of its VIASKIN® Peanut patch for peanut-allergic children ages 4-7. The patch demonstrated statistically significant efficacy with 82.8% of treated children increasing their reactive dose by at least one level versus 48% in placebo, and 60.1% increasing by at least two levels versus 23.4% in placebo. The company plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2026.

02/28/2026, 2:25 PM • GlobeNewswire